Curacle Co. Ltd.
curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company's products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition… Read more
Curacle Co. Ltd. - Asset Resilience Ratio
Curacle Co. Ltd. (365270) has an Asset Resilience Ratio of 36.01% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Curacle Co. Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Curacle Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩20.02 Billion | 36.01% |
| Total Liquid Assets | ₩20.02 Billion | 36.01% |
Asset Resilience Insights
- Very High Liquidity: Curacle Co. Ltd. maintains exceptional liquid asset reserves at 36.01% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Curacle Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Curacle Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Curacle Co. Ltd. (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Curacle Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 44.50% | ₩26.38 Billion | ₩59.29 Billion | +4.36pp |
| 2023-12-31 | 40.14% | ₩28.01 Billion | ₩69.78 Billion | -16.60pp |
| 2022-12-31 | 56.75% | ₩31.58 Billion | ₩55.66 Billion | -12.60pp |
| 2021-12-31 | 69.35% | ₩45.44 Billion | ₩65.53 Billion | -11.75pp |
| 2020-12-31 | 81.10% | ₩10.29 Billion | ₩12.69 Billion | -3.62pp |
| 2019-12-31 | 84.72% | ₩13.15 Billion | ₩15.52 Billion | -6.68pp |
| 2018-12-31 | 91.40% | ₩9.66 Billion | ₩10.56 Billion | -- |